发明名称 Combinations of AKT inhibitor compounds and erlotinib, and methods of use
摘要 The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.;
申请公布号 US9150549(B2) 申请公布日期 2015.10.06
申请号 US201214009313 申请日期 2012.03.30
申请人 Genentech, Inc. 发明人 Nannini Michelle;Sampath Deepak
分类号 A61K31/505;A61K31/517;C07D403/12;C07D239/70;A61K31/437;A61K31/496;A61K31/58;A61K31/282;A61K31/337;A61K31/4188;A61K31/4745;A61K31/513;A61K31/519;A61K31/704;A61K39/395;A61K39/00 主分类号 A61K31/505
代理机构 Viksnins Harris & Padys PLLP 代理人 Viksnins Harris & Padys PLLP
主权项 1. A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder.
地址 South San Francisco CA US